These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17183637)

  • 1. A comparative study on the cost of new antibiotics and drugs of other therapeutic categories.
    Falagas ME; Fragoulis KN; Karydis I
    PLoS One; 2006 Dec; 1(1):e11. PubMed ID: 17183637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economics of new oncology drug development.
    DiMasi JA; Grabowski HG
    J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.
    Spellberg B; Miller LG; Kuo MN; Bradley J; Scheld WM; Edwards JE
    Infection; 2007 Jun; 35(3):167-74. PubMed ID: 17565458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
    Bennett CL; Oddone E; Matchar D
    Clin Perform Qual Health Care; 1995; 3(3):156-64. PubMed ID: 10151167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
    Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
    Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The price of innovation: new estimates of drug development costs.
    DiMasi JA; Hansen RW; Grabowski HG
    J Health Econ; 2003 Mar; 22(2):151-85. PubMed ID: 12606142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of oral antibiotic therapy.
    Nightingale CH; Quintiliani R
    Pharmacotherapy; 1997; 17(2):302-7. PubMed ID: 9085322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canadian and US drug approval times and safety considerations.
    Rawson NS; Kaitin KI
    Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacoeconomics of intravenous antibiotic use in serious infection.
    Levett PN; Jennings AM; Manning KS; Harewood HC; Griffith CR; Williams CJ; Estwick D; Lashley BA
    West Indian Med J; 1995 Sep; 44(3):81-4. PubMed ID: 8560883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of new drug introduction on drug expenditure in primary health care in Catalunya, Spain.
    Zara C; Torralba M; Sotoca JM; Prat A; Faixedas MT; Gilabert A
    Ann Pharmacother; 2005 Jan; 39(1):177-82. PubMed ID: 15572601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A commentary on high-cost drugs.
    de Leon RF
    Curr Concepts Hosp Pharm Manage; 1989; 11(3):4-7. PubMed ID: 10318277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Policy implications of drug importation.
    Palumbo FB; Mullins CD; Slagle AF; Rizer J
    Clin Ther; 2007 Dec; 29(12):2758-67. PubMed ID: 18201594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug development costs when financial risk is measured using the Fama-French three-factor model.
    Vernon JA; Golec JH; Dimasi JA
    Health Econ; 2010 Aug; 19(8):1002-5. PubMed ID: 19655335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment.
    Sirinavin S; Suvanakoot P; Sathapatayavongs B; Malatham K
    Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):636-42. PubMed ID: 10437971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The generics in transplantation and the rules on their use.
    Masri M
    Exp Clin Transplant; 2003 Jun; 1(1):65-8. PubMed ID: 15859910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Drug Development: New Targets for Cancer Treatment.
    Curt GA
    Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.